Santiago GarcÃ-a-López

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9082009/publications.pdf

Version: 2024-02-01

56 papers

1,618 citations

377584 21 h-index 39 g-index

64 all docs

64
docs citations

64 times ranked 2365 citing authors

#	Article	IF	CITATIONS
1	Traducción al español y validación de un cuestionario breve de medida del control de la enfermedad inflamatoria intestinal desde la perspectiva del paciente: IBD-Control, EII-Control. GastroenterologÃa Y HepatologÃa, 2022, 45, 524-534.	0.2	3
2	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. Journal of Clinical Medicine, 2022, 11, 421.	1.0	8
3	Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study. Inflammatory Bowel Diseases, 2022, 28, 1725-1736.	0.9	27
4	Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU. Journal of Clinical Medicine, 2022, 11, 3915.	1.0	2
5	Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry. Digestive Diseases and Sciences, 2021, 66, 2014-2023.	1.1	28
6	Neumonitis por metotrexato en paciente con enfermedad de Crohn, durante la pandemia COVID: un caso clÃnico inusual y revisión de la literatura. GastroenterologÃa Y HepatologÃa, 2021, 44, 302-303.	0.2	1
7	Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, , 1-11.	0.7	2
8	Small and Large Intestine (II): Inflammatory Bowel Disease, Short Bowel Syndrome, and Malignant Tumors of the Digestive Tract. Nutrients, 2021, 13, 2325.	1.7	12
9	Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry. Journal of Crohn's and Colitis, 2021, , .	0.6	6
10	Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry. Inflammatory Bowel Diseases, 2020, 26, 606-616.	0.9	29
11	The Harvey–Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study. Telemedicine Journal and E-Health, 2020, 26, 78-86.	1.6	16
12	Realâ€world longâ€term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2020, 52, 1017-1030.	1.9	42
13	Consensus document on the management preferences of patients with ulcerative colitis: points to consider and recommendations. European Journal of Gastroenterology and Hepatology, 2020, 32, 1514-1522.	0.8	8
14	P629 Long-term effectiveness and safety of ustekinumab (UST) in patients with active Crohn's disease (CD) in real life: Interim analysis of the SUSTAIN study. Journal of Crohn's and Colitis, 2020, 14, S520-S522.	0.6	1
15	Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. Journal of Crohn's and Colitis, 2020, 14, 1290-1298.	0.6	5
16	Eficacia y seguridad de ustekinumab en la práctica clÃnica real. Estudio multicéntrico retrospectivo. Cohorte ARAINF. GastroenterologÃa Y HepatologÃa, 2020, 43, 126-132.	0.2	12
17	GuÃa GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodologÃa GRADE. GastroenterologÃa Y HepatologÃa, 2020, 43, 1-57.	0.2	24
18	P439 Effectiveness and safety of the sequential use of a second and third anti-TNF agent in patients with inflammatory bowel disease: results from the ENEIDA registry. Journal of Crohn's and Colitis, 2019, 13, S329-S330.	0.6	0

#	Article	IF	Citations
19	P437 Risk of immunomediated adverse events or secondary loss of response to infliximab in elderly patients with inflammatory bowel disease: a cohort study of the ENEIDA registry. Journal of Crohn's and Colitis, 2019, 13, S328-S329.	0.6	O
20	Increased risk of thiopurineâ€related adverse events in elderly patients with IBD. Alimentary Pharmacology and Therapeutics, 2019, 50, 780-788.	1.9	40
21	Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicentre Study. Journal of Crohn's and Colitis, 2019, 13, 996-1002.	0.6	52
22	P505 Real-world short-term effectiveness of ustekinumab in Crohn's disease: Results from the ENEIDA Registry. Journal of Crohn's and Colitis, 2019, 13, S364-S366.	0.6	2
23	P214 How to incorporate patients preference into ulcerative colitis current clinical management: initial document from a Spanish multidisciplinary steering committee. Journal of Crohn's and Colitis, 2019, 13, S202-S203.	0.6	O
24	P424 Is the switch to a second thiopurine a safe strategy in elderly patients with inflammatory bowel disease? A multi-centre cohort study of the ENEIDA registry. Journal of Crohn's and Colitis, 2019, 13, S321-S322.	0.6	1
25	PGI16 COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER BIOLOGIC FAILURE OR INTOLERANCE IN SPAIN. Value in Health, 2019, 22, S619.	0.1	2
26	PGI17 COST-EFFECTIVENESS OF TOFACTINIB FOR THE TREATMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS AFTER CONVENTIONAL THERAPY IN SPAIN. Value in Health, 2019, 22, S619.	0.1	2
27	Ustekinumab en un paciente con pioderma gangrenoso y enfermedad de Crohn refractaria. Medicina ClÃnica, 2019, 153, e35-e36.	0.3	5
28	Pioderma gangrenoso bilateral asociado a colitis ulcerosa y proctocolectomÃa restauradora. GastroenterologÃa Y HepatologÃa, 2019, 42, 441-442.	0.2	0
29	No siempre es una enfermedad de Crohn: amebiasis como diagnóstico diferencial de la enfermedad inflamatoria intestinal. GastroenterologÃa Y HepatologÃa, 2019, 42, 548-549.	0.2	3
30	Enfisema subcutÃ;neo secundario a perforación intestinal en paciente con enfermedad de Crohn. GastroenterologÃa Y HepatologÃa, 2019, 42, 636-637.	0.2	0
31	Toll-like receptors 2 and 4 modulate intestinal IL-10 differently in ileum and colon. United European Gastroenterology Journal, 2018, 6, 446-453.	1.6	22
32	OP034 The initiation of thiopurines in elderly patients with inflammatory bowel disease is associated with an increased risk of adverse effects: a case–control study of the ENEIDA registry. Journal of Crohn's and Colitis, 2018, 12, S023-S025.	0.6	4
33	P391 The availability of anti-TNF agents is associated with reduced early surgical requirements in Crohn's disease but not in ulcerative colitis. A nationwide study from the Eneida registry. Journal of Crohn's and Colitis, 2018, 12, S301-S302.	0.6	2
34	Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. International Journal of Clinical Pharmacy, 2018, 40, 1411-1419.	1.0	33
35	Short and longâ€term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2018, 48, 839-851.	1.9	71
36	P425 Proactive measurement of infliximab trough levels vs. clinical management in inflammatory bowel disease: multicentre study. Journal of Crohn's and Colitis, 2018, 12, S319-S320.	0.6	0

#	Article	IF	Citations
37	Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. American Journal of Gastroenterology, 2017, 112, 120-131.	0.2	93
38	Incidence and Management of Recurrence in Patients with Crohn $\hat{E}^{1}\!\!/_{4}$ s Disease Who Have Undergone Intestinal Resection. Inflammatory Bowel Diseases, 2017, 23, 1840-1846.	0.9	22
39	Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naÃ-ve and non-naÃ-ve patients. Journal of Gastroenterology, 2017, 52, 788-799.	2.3	50
40	Oral Cyanocobalamin is Effective in the Treatment of Vitamin B12 Deficiency in Crohn's Disease. Nutrients, 2017, 9, 308.	1.7	15
41	P327 Evolution after a "de-intensification―strategy with anti-TNF therapy in patients with inflammatory bowel disease in clinical remission: multicenter study. Journal of Crohn's and Colitis, 2017, 11, S243-S243.	0.6	2
42	Enfermedad inflamatoria intestinal en la Digestive Disease Week 2016: novedades en epidemiologÃa, seguimiento, monitorización y control terapéutico, y prevención del cáncer de colon. GastroenterologÃa Y HepatologÃa, 2016, 39, 29-35.	0.2	0
43	SÃndrome de malabsorción. Medicine, 2016, 12, 159-167.	0.0	O
44	High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life. Blood Transfusion, 2016, 14, 199-205.	0.3	19
45	Risk of Upper and Lower Gastrointestinal Bleeding in Patients Taking Nonsteroidal Anti-inflammatory Drugs, Antiplatelet Agents, or Anticoagulants. Clinical Gastroenterology and Hepatology, 2015, 13, 906-912.e2.	2.4	207
46	Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata. Scandinavian Journal of Gastroenterology, 2014, 49, 1181-1190.	0.6	10
47	The GETECCU clinical guideline for the treatment of ulcerative colitis: A guideline created using GRADE methodology. GastroenterologÃa Y HepatologÃa, 2013, 36, 483.e1-483.e46.	0.2	2
48	Therapeutic guidelines on ulcerative colitis: A GRADE methodology based effort of GETECCU. GastroenterologÃa Y HepatologÃa, 2013, 36, 104-114.	0.2	44
49	Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2013, 108, 433-440.	0.2	197
50	Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial. Scandinavian Journal of Gastroenterology, 2013, 48, 285-294.	0.6	6
51	Optimal management of iron deficiency anemia due to poor dietary intake. International Journal of General Medicine, 2011, 4, 741.	0.8	50
52	The changing face of hospitalisation due to gastrointestinal bleeding and perforation. Alimentary Pharmacology and Therapeutics, 2011, 33, 585-591.	1.9	137
53	Actualizacion en el tratamiento de la colitis ulcerosa. GastroenterologÃa Y HepatologÃa, 2011, 34, 53-58.	0.2	O
54	A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World Journal of Gastroenterology, 2009, 15, 4638.	1.4	157

ı	#	Article	IF	CITATIONS
	55	Cyclosporine in the treatment of severe attack of ulcerative colitis: a systematic review. GastroenterologÃa Y HepatologÃa, 2005, 28, 607-614.	0.2	67
	56	Successful Endoscopic Relief of Large Bowel Obstruction in a Case of a Sigmoid Colon Gallstone Ileus. Journal of Clinical Gastroenterology, 1997, 24, 291-292.	1.1	14